Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: AMT

Gene summary for AMT

Gene summary.

Gene information	Species	Human
	Gene symbol	AMT
	Gene ID	275
	Gene name	aminomethyltransferase
	Gene Alias	GCE
	Cytomap	3p21.31
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	A0A024R2U7

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
275	AMT	HCC1_Meng	Human	Liver	HCC	2.62e-95	1.65e-01	0.0246
275	AMT	HCC2_Meng	Human	Liver	HCC	3.00e-03	-2.33e-03	0.0107
275	AMT	cirrhotic1	Human	Liver	Cirrhotic	1.38e-02	8.85e-02	0.0202
275	AMT	cirrhotic2	Human	Liver	Cirrhotic	8.19e-04	1.33e-01	0.0201
275	AMT	HCC1	Human	Liver	HCC	5.22e-06	3.21e+00	0.5336
275	AMT	HCC2	Human	Liver	HCC	1.20e-02	1.68e+00	0.5341
275	AMT	S015	Human	Liver	HCC	6.02e-04	3.38e-01	0.2375
275	AMT	S016	Human	Liver	HCC	2.72e-03	2.44e-01	0.2243

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00510925	Oral cavity	OSCC	positive regulation of NF-kappaB transcription factor activity	82/7305	152/18723	1.28e-04	9.13e-04	82
GO:00011019	Oral cavity	OSCC	response to acid chemical	74/7305	135/18723	1.38e-04	9.76e-04	74
GO:00160537	Oral cavity	OSCC	organic acid biosynthetic process	155/7305	316/18723	1.64e-04	1.13e-03	155
GO:004311210	Oral cavity	OSCC	receptor metabolic process	88/7305	166/18723	1.68e-04	1.15e-03	88
GO:00463947	Oral cavity	OSCC	carboxylic acid biosynthetic process	154/7305	314/18723	1.73e-04	1.19e-03	154
GO:009013018	Oral cavity	OSCC	tissue migration	176/7305	365/18723	1.92e-04	1.29e-03	176
GO:005134618	Oral cavity	OSCC	negative regulation of hydrolase activity	182/7305	379/18723	1.98e-04	1.32e-03	182
GO:00091001	Oral cavity	OSCC	glycoprotein metabolic process	185/7305	387/18723	2.37e-04	1.54e-03	185
GO:001095117	Oral cavity	OSCC	negative regulation of endopeptidase activity	126/7305	252/18723	2.37e-04	1.54e-03	126
GO:001046618	Oral cavity	OSCC	negative regulation of peptidase activity	130/7305	262/18723	2.89e-04	1.82e-03	130
GO:00432006	Oral cavity	OSCC	response to amino acid	64/7305	116/18723	2.96e-04	1.86e-03	64
GO:19011361	Oral cavity	OSCC	carbohydrate derivative catabolic process	89/7305	172/18723	4.52e-04	2.73e-03	89
GO:00712304	Oral cavity	OSCC	cellular response to amino acid stimulus	42/7305	71/18723	4.59e-04	2.76e-03	42
GO:00301983	Oral cavity	OSCC	extracellular matrix organization	146/7305	301/18723	4.67e-04	2.77e-03	146
GO:00353073	Oral cavity	OSCC	positive regulation of protein dephosphorylation	29/7305	45/18723	4.85e-04	2.86e-03	29
GO:00452293	Oral cavity	OSCC	external encapsulating structure organization	147/7305	304/18723	5.30e-04	3.08e-03	147
GO:005110120	Oral cavity	OSCC	regulation of DNA binding	64/7305	118/18723	5.53e-04	3.21e-03	64
GO:00430623	Oral cavity	OSCC	extracellular structure organization	146/7305	302/18723	5.59e-04	3.23e-03	146
GO:00712295	Oral cavity	OSCC	cellular response to acid chemical	46/7305	80/18723	6.08e-04	3.44e-03	46
GO:00083618	Oral cavity	OSCC	regulation of cell size	92/7305	181/18723	7.86e-04	4.26e-03	92

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0120021	Liver	Cirrhotic	Carbon metabolism	64/2530	115/8465	6.37e-09	1.18e-07	7.26e-08	64
hsa006304	Liver	Cirrhotic	Glyoxylate and dicarboxylate metabolism	20/2530	30/8465	3.36e-05	2.54e-04	1.57e-04	20
hsa00260	Liver	Cirrhotic	Glycine, serine and threonine metabolism	22/2530	40/8465	7.85e-04	4.51e-03	2.78e-03	22
hsa0120031	Liver	Cirrhotic	Carbon metabolism	64/2530	115/8465	6.37e-09	1.18e-07	7.26e-08	64
hsa0063011	Liver	Cirrhotic	Glyoxylate and dicarboxylate metabolism	20/2530	30/8465	3.36e-05	2.54e-04	1.57e-04	20
hsa002601	Liver	Cirrhotic	Glycine, serine and threonine metabolism	22/2530	40/8465	7.85e-04	4.51e-03	2.78e-03	22
hsa0120041	Liver	HCC	Carbon metabolism	89/4020	115/8465	3.92e-11	6.56e-10	3.65e-10	89
hsa0063021	Liver	HCC	Glyoxylate and dicarboxylate metabolism	24/4020	30/8465	2.66e-04	1.24e-03	6.88e-04	24
hsa006702	Liver	HCC	One carbon pool by folate	17/4020	20/8465	6.04e-04	2.50e-03	1.39e-03	17
hsa002602	Liver	HCC	Glycine, serine and threonine metabolism	28/4020	40/8465	3.28e-03	1.07e-02	5.93e-03	28
hsa0120051	Liver	HCC	Carbon metabolism	89/4020	115/8465	3.92e-11	6.56e-10	3.65e-10	89
hsa0063031	Liver	HCC	Glyoxylate and dicarboxylate metabolism	24/4020	30/8465	2.66e-04	1.24e-03	6.88e-04	24
hsa0067011	Liver	HCC	One carbon pool by folate	17/4020	20/8465	6.04e-04	2.50e-03	1.39e-03	17
hsa002603	Liver	HCC	Glycine, serine and threonine metabolism	28/4020	40/8465	3.28e-03	1.07e-02	5.93e-03	28

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

AMT

insertion

In_Frame_Ins

novel

c.958_959insAGGTCCAGGGCTACA

p.Arg320delinsGlnValGlnGlyTyrSer

p.R320delinsQVQGYS

P48728

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

AMT

insertion

Frame_Shift_Ins

novel

c.1047_1048insAAGGAAGTAAATTTAAGATGGATATTTAA

p.Gly350LysfsTer17

p.G350Kfs*17

P48728

protein_coding

TCGA-A8-A07G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

5-fluorouracil

AMT

insertion

In_Frame_Ins

novel

c.1053_1054insACTTCCGTGTTTAAT

p.Cys351_Pro352insThrSerValPheAsn

p.C351_P352insTSVFN

P48728

protein_coding

TCGA-AR-A0TY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

AMT

SNV

Missense_Mutation

c.468N>T

p.Met156Ile

p.M156I

P48728

protein_coding

tolerated(0.76)

benign(0.103)

TCGA-AA-3492-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

AMT

SNV

Missense_Mutation

rs749087037

c.59N>T

p.Pro20Leu

p.P20L

P48728

protein_coding

tolerated(0.4)

benign(0)

TCGA-AZ-6598-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

AMT

SNV

Missense_Mutation

c.791T>A

p.Leu264Gln

p.L264Q

P48728

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-CM-6166-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

AMT

SNV

Missense_Mutation

rs372496075

c.583N>A

p.Val195Met

p.V195M

P48728

protein_coding

tolerated(0.06)

possibly_damaging(0.503)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

AMT

SNV

Missense_Mutation

novel

c.901N>A

p.Asp301Asn

p.D301N

P48728

protein_coding

tolerated(0.32)

benign(0.129)

TCGA-AJ-A3EL-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

AMT

SNV

Missense_Mutation

c.587C>T

p.Ala196Val

p.A196V

P48728

protein_coding

tolerated(0.2)

benign(0.041)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

AMT

SNV

Missense_Mutation

novel

c.505N>T

p.Asp169Tyr

p.D169Y

P48728

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-EO-A3B0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1